SJS Investment Consulting’s Intellia Therapeutics NTLA Stock Holding History

SJS Investment Consulting’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.44K	Buy	203 +158	+351%	+$2.21K	﹤0.01%	1546
2026 Q1	$578	Buy	45 +20	+80%	+$255	﹤0.01%	1678
2025 Q4	$225	Hold	25	–	–	﹤0.01%	1773
2025 Q3	$432	Hold	25	–	–	﹤0.01%	1278
2025 Q2	$235	Hold	25	–	–	﹤0.01%	1328
2025 Q1	$178	Hold	25	–	–	﹤0.01%	1465
2024 Q4	$292	Sell	25 -1	-4%	-$16	﹤0.01%	1399
2024 Q3	$535	Sell	26 -2	-7%	-$46	﹤0.01%	1301
2024 Q2	$628	Hold	28	–	–	﹤0.01%	1215
2024 Q1	$771	Hold	28	–	–	﹤0.01%	1131
2023 Q4	$855	Buy	28 +1	+4%	+$29	﹤0.01%	1014
2023 Q3	$855	Buy	27 +2	+8%	+$78	﹤0.01%	1006
2023 Q2	$1.02K	Hold	25	–	–	﹤0.01%	897
2023 Q1	$932	Hold	25	–	–	﹤0.01%	920
2022 Q4	$872	Hold	25	–	–	﹤0.01%	1004
2022 Q3	$1K	Buy	+25	New	+$1.55K	﹤0.01%	839
2022 Q1	$16K	Hold	225	–	–	﹤0.01%	331
2021 Q4	$27K	Buy	+225	New	+$28.2K	0.01%	232

Other funds holding NTLA

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

CIC

Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

BEI

Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

TGIA

Torrey Growth & Income Advisors Del Mar, California $294M AUM 37.95% 1-Year Est. Return

SJS Investment Consulting's NTLA Position: Q2 2026 in Review

SJS Investment Consulting increased its Intellia Therapeutics (NTLA) stake by 351% in Q2 2026, buying an estimated $2.21K and bringing the position to 203 shares worth $3.44K. The position accounts for ﹤0.01% of the portfolio, ranked #1546.

SJS Investment Consulting first reported a position in NTLA in Q4 2021 and has held it in 18 quarters since. The position peaked at $27K in Q4 2021. 78 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

SJS Investment Consulting held 203 shares of Intellia Therapeutics worth $3.44K as of Q2 2026.
SJS Investment Consulting bought 158 Intellia Therapeutics shares in Q2 2026, an estimated $2.21K.
Intellia Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1546 holding.
SJS Investment Consulting first reported a position in Intellia Therapeutics in Q4 2021 and has held it in 18 quarters since.
SJS Investment Consulting's Intellia Therapeutics position peaked at $27K in Q4 2021.
78 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.